NASDAQ:NVCT Nuvectis Pharma (NVCT) Stock Price, News & Analysis $10.20 +0.10 (+0.94%) As of 02:09 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Nuvectis Pharma Stock (NASDAQ:NVCT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Nuvectis Pharma alerts:Sign Up Key Stats Today's Range$9.92▼$10.5050-Day Range$7.48▼$12.4552-Week Range$5.55▼$13.34Volume88,506 shsAverage Volume73,000 shsMarket Capitalization$270.47 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingHold Company Overview Nuvectis Pharma is a clinical-stage biotechnology company focused on the development of novel peptide-based therapeutics using its proprietary Cellporting delivery platform. The company’s core technology is designed to facilitate the transport of therapeutic proteins and peptides across cellular membranes and into target intracellular compartments, including the nucleus. By overcoming a key barrier in biologics delivery, Nuvectis aims to expand the range of treatable diseases with macromolecular drugs that have traditionally been limited by poor cellular uptake. The Nuvectis pipeline encompasses multiple preclinical and early-stage clinical programs targeting rare genetic and metabolic disorders. Lead candidates are being evaluated for inherited conditions characterized by enzyme deficiencies or receptor dysfunction, with the goal of delivering active protein payloads directly to affected cells. In parallel, the company is exploring applications of its delivery technology in areas such as oncology and inflammatory disease, seeking strategic partnerships to advance select programs into later clinical development. Headquartered in San Diego, California, Nuvectis Pharma operates with a management team drawn from established life-science and pharmaceutical backgrounds. The company maintains research collaborations with academic centers and contract development organizations to accelerate its discovery and development activities. With a focus on rare diseases and high-unmet-need patient populations, Nuvectis is positioning its platform to address therapeutic challenges that extend beyond the reach of conventional biologic and small-molecule approaches. AI Generated. May Contain Errors. Read More Nuvectis Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks17th Percentile Overall ScoreNVCT MarketRank™: Nuvectis Pharma scored higher than 17% of companies evaluated by MarketBeat, and ranked 801st out of 867 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.0 / 5Analyst RatingHold Consensus RatingNuvectis Pharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Nuvectis Pharma is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageNuvectis Pharma has received no research coverage in the past 90 days.Read more about Nuvectis Pharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Nuvectis Pharma are expected to grow in the coming year, from ($1.01) to ($0.98) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nuvectis Pharma is -7.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nuvectis Pharma is -7.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNuvectis Pharma has a P/B Ratio of 19.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Nuvectis Pharma's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.94% of the float of Nuvectis Pharma has been sold short.Short Interest Ratio / Days to CoverNuvectis Pharma has a short interest ratio ("days to cover") of 29.81, which indicates bearish sentiment.Change versus previous monthShort interest in Nuvectis Pharma has recently decreased by 5.00%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNuvectis Pharma does not currently pay a dividend.Dividend GrowthNuvectis Pharma does not have a long track record of dividend growth. News and Social Media3.1 / 5News SentimentN/A News SentimentNuvectis Pharma has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.MarketBeat Follows1 people have added Nuvectis Pharma to their MarketBeat watchlist in the last 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Nuvectis Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders30.52% of the stock of Nuvectis Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.77% of the stock of Nuvectis Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Nuvectis Pharma's insider trading history. Receive NVCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nuvectis Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NVCT Stock News HeadlinesNuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQMay 14, 2026 | globenewswire.comNuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business HighlightsMay 5, 2026 | globenewswire.comBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.May 27 at 1:00 AM | Weiss Ratings (Ad)Insider Stock Buying Reaches US$2.07m On Nuvectis PharmaMay 4, 2026 | finance.yahoo.comNuvectis Pharma (NVCT) price target decreased by 11.71% to 16.66April 28, 2026 | msn.comNuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research MeetingMarch 31, 2026 | globenewswire.comHere's Why We're Not Too Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn SituationMarch 24, 2026 | finance.yahoo.comNuvectis Pharma Reports 2025 Financial Results and Progress in NXP900 Development ProgramFebruary 11, 2026 | quiverquant.comQSee More Headlines NVCT Stock Analysis - Frequently Asked Questions How have NVCT shares performed this year? Nuvectis Pharma's stock was trading at $7.55 at the start of the year. Since then, NVCT stock has increased by 38.3% and is now trading at $10.4420. How were Nuvectis Pharma's earnings last quarter? Nuvectis Pharma, Inc. (NASDAQ:NVCT) announced its earnings results on Tuesday, May, 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.30) by $0.04. When did Nuvectis Pharma IPO? Nuvectis Pharma (NVCT) raised $19 million in an initial public offering (IPO) on Friday, February 4th 2022. The company issued 3,200,000 shares at a price of $5.00-$7.00 per share. Who are Nuvectis Pharma's major shareholders? Nuvectis Pharma's top institutional investors include Bank of New York Mellon Corp (0.11%) and Bank of America Corp DE (0.06%). Insiders that own company stock include Marlio Charles Mosseri, Enrique Poradosu, Matthew L Kaplan and Juan Sanchez. View institutional ownership trends. How do I buy shares of Nuvectis Pharma? Shares of NVCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nuvectis Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nuvectis Pharma investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Invesco QQQ (QQQ), Tesla (TSLA), Meta Platforms (META), JPMorgan Chase & Co. (JPM) and Netflix (NFLX). Company Calendar Last Earnings5/05/2026Today5/27/2026Next Earnings (Estimated)8/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 NVCT's financial health is in the Green zone, according to TradeSmith. NVCT has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NVCT CIK1875558 Webwww.nuvectis.com Phone201-614-3150FaxN/AEmployees8Year Founded2020Price Target and Rating Average Price Target for Nuvectis Pharma$10.00 High Price Target$10.00 Low Price Target$10.00 Potential Upside/Downside-1.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($1.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$26.44 million Net MarginsN/A Pretax MarginN/A Return on Equity-161.00% Return on Assets-98.88% Debt Debt-to-Equity RatioN/A Current Ratio2.27 Quick Ratio2.27 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.54 per share Price / Book18.88Miscellaneous Outstanding Shares26,530,000Free Float18,430,000Market Cap$270.47 million OptionableNot Optionable Beta-0.11 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:NVCT) was last updated on 5/27/2026 by MarketBeat.com Staff. From Our PartnersThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...American Alternative | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvectis Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvectis Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
